GLP-1 medications have emerged as a powerful weapon against obesity and diabetes, but at nearly $1,000 a month, they're forcing payors and patients into a difficult financial balancing act. This post explores how Medicare, commercial insurers, and employers are grappling with coverage decisions, why some plans are reversing course amid budget concerns, and whether tying access to lifestyle modification programs could offer a sustainable middle ground between innovation and co

Glucagon-like peptide-1 (GLP-1) receptor agonists seem to be everywhere today. Whether it be an article highlighting a pharmaceutical